MFRP , PRSS56 , and MYRF account for 60.5% of a Chinese cohort with nanophthalmos
Clinical & Experimental Ophthalmology · 2025
DOI: 10.1111/ceo.14465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Jing Tao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Membrane Proteins, Microphthalmos, Mutation, Serine Proteases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Nova Program.
Abstract (Originalsprache)
Background
This study aimed to present the genetic profile of a rare ocular disease nanophthalmos (NO) in a large Chinese cohort, to explore its genetic characteristics and genotype–phenotype correlations.
Methods
A total of 43 unrelated pedigrees diagnosed with NO were recruited. Whole exome sequencing and copy number variation analysis were performed, followed by validation and pathogenicity classification of the detected variants.
Results
The overall genetic diagnostic rate was 60.5%. Twenty‐eight unique genetic variants of MFRP , PRSS56 , and MYRF have been identified, of which 19 were reported for the first time. The c.1486G>A variant in MFRP and the c.1066dupC variant in PRSS56 were the two most frequent variants. Patients with variants in MFRP or PRSS56 tended to possess shorter axial lengths than those with MYRF variants. Among patients with MFRP null variants, a higher proportion developed uveal effusion syndrome (UES) than did those without null variants, whereas among patients with PRSS56 null variants, a greater number of patients developed angle‐closure glaucoma (ACG). A higher proportion of MFRP ‐related NO patients developed both UES and ACG.
Conclusions
MFRP, PRSS56 , and MYRF account for the majority of genetic causes of NO. MFRP ‐related NO patients tend to exhibit a strong predisposition to complications. Null variants in MFRP and PRSS56 may increase susceptibility to clinical complications. This study provides insights into the genetic landscape and clinical characteristics of NO. These findings will lead to a better understanding of the mechanisms underlying nanophthalmos and other diseases associated with eye development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Zi-Bing Jin
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Beijing Nova Program
- Beijing Municipal Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Tao, J., Jin, Z. B., & Shen, R. J. (2025). MFRP , PRSS56 , and MYRF account for 60.5% of a Chinese cohort with nanophthalmos. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14465
Vancouver
Tao J, Jin ZB, Shen RJ. MFRP , PRSS56 , and MYRF account for 60.5% of a Chinese cohort with nanophthalmos. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.14465
BibTeX
@article{Tao2025,
author = {Tao, Jing and Jin, Zi-Bing and Shen, Ren-Juan},
title = {MFRP , PRSS56 , and MYRF account for 60.5% of a Chinese cohort with nanophthalmos},
journal = {Clinical & Experimental Ophthalmology},
year = {2025},
doi = {10.1111/ceo.14465}
}
EUVIMED